Videos

Jared S. Winoker, MD, addresses the wide range of stone burdens treated by the CVAC system for the study.

Panelists discuss how pembrolizumab, a PD-1 inhibitor, offers a systemic immunotherapy option for high-risk, BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC) by enhancing the immune system’s ability to target cancer cells, with intravenous administration and careful monitoring for immune-related adverse effects.

Paul E. Dato, MD, discusses how a 63-year-old Black man with recurrent hormone-sensitive prostate cancer (HSPC) presented with high-grade disease and multiple metastases after initial prostatectomy, requiring accurate staging and comprehensive treatment planning.

Paul E. Dato, MD, discusses how patient-specific factors such as age, tumor volume, comorbidities, and treatment adherence are critical for therapy selection, emphasizing the importance of assessing frailty rather than age alone and the value of multidisciplinary care.

Panelists discuss how recently FDA-approved therapies, including nadofaragene firadenovec, gemcitabine, and docetaxel, offer alternative treatment options for BCG-unresponsive high-risk non–muscle-invasive bladder cancer (NMIBC), each with distinct mechanisms and administration methods.

A prostate cancer expert breaks down likelihood of a diagnosis of metastatic prostate cancer and touches on available treatment options.

The AI tool outperformed MRI in assessing for SVI.

Karyn S. Eilber, MD, discusses treatment of genitourinary syndrome of menopause.

The risk of stricture formation was 4.6% in the TFL cohort vs 2.4% in the holmium laser cohort.

According to Adam B. Weiner, MD, a urologist at Cedars-Sinai Medical Center, men should begin prostate cancer screening around ages 50 to 55.

"There was a significant increase in overall fatigue after performing flexible ureteroscopy," says Sarah Razavi, MD.

Research reveals that lower PSA levels in metastatic hormone-sensitive prostate cancer significantly delay disease progression and improve patient outcomes.

Explore treatment options for small renal masses, including surveillance, surgery, and biopsy, while understanding the role of ccRCC PET in diagnosis.

Explore the latest advancements in metastatic hormone-sensitive prostate cancer treatment, highlighting effective agents and clinical trial outcomes.

Explore the strengths and weaknesses of imaging modalities like CT, MRI, and ultrasound in diagnosing ccRCC and enhancing patient care.

Panelist discusses how hospitals benefit from adopting aqua ablation therapy by improving surgical efficiency, reducing turnover times, enabling outpatient procedures, and providing a highly effective treatment option that can enhance patient outcomes while preserving sexual function.

Explore the critical underrepresentation of black men in metastatic hormone sensitive prostate cancer trials and its implications for treatment outcomes.

Research highlights the significant benefits of achieving ultra-low PSA levels in metastatic hormone-sensitive prostate cancer, delaying disease progression effectively.

“I think it does give us confidence that clinical trials can predict how these drugs will work in the real world," says Stephen J. Freedland, MD.

Panelists discuss how non–muscle-invasive bladder cancer (NMIBC) is staged, graded, and treated according to risk stratification, with detailed explanations of low-, intermediate-, and high-risk categories and corresponding treatment pathways.

“The key finding is [that] this might be, in itself, a novel risk factor for bladder cancer," says Laura E. Davis, MD.

Nearly 60% of patients taking vibegron remained on treatment at 1 year.

Panelists discuss how maintenance BCG therapy and vigilant surveillance are essential for sustaining disease control in NMIBC patients, with treatment schedules and monitoring tailored to individual risk and tolerance.

Paul E. Dato, MD, discusses how the presence of a BRCA mutation can influence treatment selection and sequencing, supporting consideration of upfront triplet therapy intensification and planning for earlier integration of PARP inhibitors when castration resistance develops.

Paul E. Dato, MD, discusses how formulation and dosing differences between abiraterone options affect absorption and tolerability, with the micronized version potentially providing better compliance due to no fasting requirement, though insurance coverage remains a significant hurdle for its use.

Panelists discuss how timely identification of BCG-unresponsive NMIBC through defined response criteria enables dynamic risk stratification and guides critical decisions about escalating care to alternative treatments.

An expert details key post-procedural recommendations following onabotulinumtoxinA injection for OAB.

Recent data suggest that obesity may be a risk factor for increased pain on transperineal biopsy.

An expert walks through specific actions that urologists and their teams can take before, during, and after the procedure.

"The black box warning affects that ability for them to get access to that critical drug, vaginal estrogen," says Yahir A. Santiago-Lastra, MD.